All News

As companies make headway with Web promotions, their marketers express concerns about how best to benchmark online efforts.

Blog entries about branded drugs-both positive and negative-are turning up in online keyword searches. Should pharma be worried?

Vote

Japanese drugmaker buys the cancer-specialist biotech for a whopping $8.8 billion.

GSK, Pfizer, and Merck have jumped on the cell-phone marketing bandwagon, but most of pharma is still tiptoeing around the technology. A new report details how pharma can get consumers to text for health info.

With M&As the new R&D and sales forces getting axed, the CFO is transitioning from background player to front man. A new survey documents the changing role of the pharma controller.

While some drugmakers are being pummeled for data on their "bad" cholesterol?lowering drugs, promising Phase II stats about its "good" cholesterol?raising CETP inhibitor has Roche smiling. Can it escape the torcetrapib curse?

California's plan for full-blown ePedigree implementation by 2009 just got a reality check. The hang-up? The systems are cost more and are taking longer than expected to get up and running.

Veteran salesperson Reggie Smith of Genentech makes the case for sales force diversity

International outsourcing carries risks for marketers and regulatory challenges for FDA

The real question in the Baxter heparin scandal is not who's guilty but whether pharma can get reliable results from a country in chaos

When it comes to developing novel therapies from the animal kingdom, it's mostly a game of pick your poison

The real question in the Baxter heparin scandal is not who's guilty but whether pharma can get reliable results from a country in chaos

A new study looks at the movement of thought leaders and medical science liaisons from primarily marketing to other areas of the pharma company. Though the shift might be minor (7 percent since 2002), it might be a sign of things to come.

Now that Apple has opened its iPhone to third-party software developers, healthcare productivity programs are leading the charge. Here?s a preview of one of the frontrunners.

What will the next president really mean for US healthcare policy? PwC's Sandy Lutz reports.

The US pharma market grew just 3.8 percent last year, according to IMS Health. The big loser: lipid regulators. The winners: Biologic response modulators and monoclonal antibodies.

Pharma is still having a hard time earning the confidence of the key opinion elite, as only 56 percent claim they trust the industry.

A Kaiser Foundation study finds that although most Americans look favorably upon pharmaceuticals, they generally think drugs are too expensive and that most of the cost is blown on advertising.

PACME final brochure

PACME brochure

A review of a pilot ePrescribing program reveals that if physicians are given the proper support, the technology can increase safer prescribing habits and boost compliance.

Congress is firing plenty of ammunition at pharma companies-and the regulators

Pharma companies must quit wasting money and get strategic when mapping out their clinical study strategies

The industry needs credibility with consumers to make a spoonful of risk go down. So how does pharma speak to top concerns?

IAG Research released its top-10 list of most-recalled new pharma ads of 2007. Many familiar faces top the list, including the Nasonex bee, Abe Lincoln, and Dr. Jarvik, but how many of those faces will still be there next year?

Avenue A|Razorfish's new digital-outlook report indicates that pharma is still floundering online. Though some pharma companies are taking steps to make their online presence known, others are still crawling.

Under pressure from Congress and public scrutiny, Pfizer voluntarily pulled its controversial television campaign for Lipitor featuring Dr. Jarvik.